Novartis Cites Trial Evidence in Bid to Block MSN Entresto Copy

Novartis AG already provided evidence that proves MSN Laboratories Ltd.'s proposed copies of Entresto infringe a key patent for the heart-disease drug, it said in a redacted filing.

Novartis filed the public version of its June 9 opening brief supporting its second preliminary injunction motion based on US Patent No. 11,096,918 on Monday in the US District Court for the District of Delaware. MSN filed its response to the sealed filing June 27, calling Novartis’ motion “a regurgitation of its post-trial briefing and last year’s failed preliminary-injunction motion.”

Unless Judge Richard G. Andrews rules before July 16, at which point ...